Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma
Male
0301 basic medicine
0303 health sciences
Carcinoma, Hepatocellular
Liver Neoplasms
Aldo-Keto Reductase Family 1 Member C3
Down-Regulation
Hep G2 Cells
Middle Aged
Prognosis
3. Good health
03 medical and health sciences
Gene Ontology
Area Under Curve
Case-Control Studies
Cell Line, Tumor
Gene Knockdown Techniques
Humans
Female
Protein Interaction Maps
RNA, Messenger
Oxidoreductases
Research Paper
Cell Proliferation
Proportional Hazards Models
DOI:
10.18632/aging.202380
Publication Date:
2021-01-22T15:24:48Z
AUTHORS (7)
ABSTRACT
Hepatocellular carcinoma (HCC) is the most common histological type of primary liver cancer and majority patients are diagnosed at an advanced stage have a poor prognosis. AKR1C3 (Aldo-keto reductase family 1 member C3) AKR1D1 D1) catalyze conversion aldehydes ketones to alcohols play crucial roles in multiple cancers. However, functions HCC remain unclear. In our study, data from public databases were selected as training validation sets, then 76 center chosen test set. Bioinformatics methods suggested was overexpressed down-regulated. The receiver operating characteristic curve (ROC) analysis performed area under (AUC) values above 0.7 (0.948, 0.836, respectively). Also, high expression low predicted prognosis short median survival time. Then, knockdown overexpression cells achieved with lentivirus. And both decreased cell proliferation, restrained viability, inhibited tumorigenesis. Moreover, gene ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) enrichment analyses conducted results showed that might participate MAPK/ERK androgen receptor (AR) signaling pathway. Furthermore, AR phosphorylated ERK1/2 significantly reduced after suppression or AKR1D1. Collectively, serve candidate diagnostic prognostic biomarkers for provide potential targets treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (45)
CITATIONS (19)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....